As­traZeneca taps more Chi­na-de­rived tech with $19M can­cer deal for Nona an­ti­bod­ies

As­traZeneca on Thurs­day inked a li­cense and op­tion deal with the US off­shoot of a Chi­nese-Dutch com­pa­ny, with an eye to cre­at­ing an­ti­body-based tar­get­ed can­cer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER